{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:59:12Z","timestamp":1790913552677,"version":"4.1.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":178,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015693","name":"Research Institute for Gastroenterology and Liver Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101301","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:58:31Z","timestamp":1783036711000},"page":"101301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological approaches for colitis associated colorectal cancer: a survey in preclinical studies"],"prefix":"10.1016","volume":"48","author":[{"given":"Erfan","family":"Abdollahizad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7956-9712","authenticated-orcid":false,"given":"Anna","family":"Meyfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101301_bib0001","article-title":"Advances in research on the effectiveness and mechanism of traditional Chinese medicine formulas for colitis-associated colorectal cancer","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0002","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/apt.16781","article-title":"Review article: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions","volume":"55","author":"Schreiber","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2026.101301_bib0003","first-page":"16","article-title":"Gut microbiota and macrophage crosstalk: implications for colitis-associated colorectal cancer","author":"Lyu","year":"2026","journal-title":"Front. Cell Infect. Microbiol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0004","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/cells14030162","article-title":"Molecular mechanisms and clinical aspects of colitis-associated cancer in ulcerative colitis","volume":"14","author":"Yamamoto-Furusho","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2026.101301_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5126048","article-title":"The role of proinflammatory pathways in the pathogenesis of colitis-associated colorectal cancer","volume":"2017","author":"Luo","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ctarc.2026.101301_bib0006","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3390\/cancers15082389","article-title":"Inflammation-driven colorectal cancer associated with colitis: from pathogenesis to changing therapy","volume":"15","author":"Nardone","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101301_bib0007","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41575-026-01197-6","article-title":"Pathophysiology of colitis-associated colorectal cancer","volume":"23","author":"Neufert","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0008","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","article-title":"Colorectal cancer in inflammatory bowel disease: mechanisms and management","volume":"162","author":"Shah","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctarc.2026.101301_bib0009","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.dld.2021.01.012","article-title":"From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: pathogenesis and impact of current therapies","volume":"53","author":"Fantini","year":"2021","journal-title":"Dig. Liver. Dis."},{"key":"10.1016\/j.ctarc.2026.101301_bib0010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3390\/microorganisms10071371","article-title":"Gut microbiome in inflammatory bowel disease: role in pathogenesis, dietary modulation, and colitis-associated colon cancer","volume":"10","author":"Gubatan","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.ctarc.2026.101301_bib0011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/toxins17060305","article-title":"Biological mechanisms of enterotoxigenic bacteroides fragilis toxin: linking inflammation, colorectal cancer, and clinical implications","volume":"17","author":"Jasemi","year":"2025","journal-title":"Toxins"},{"key":"10.1016\/j.ctarc.2026.101301_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117292","article-title":"Integration of microbiome, metabolomics and transcriptome for in-depth understanding of berberine attenuates AOM\/DSS-induced colitis-associated colorectal cancer","volume":"179","author":"Wang","year":"2024","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.ctarc.2026.101301_bib0013","doi-asserted-by":"crossref","DOI":"10.1007\/s13659-026-00602-6","article-title":"Natural triterpenoid Ardisiacrispin B attenuates colitis-associated cancer via JAK2\/STAT3 pathway and gut microbiota modulation","volume":"16","author":"Ullah","year":"2026","journal-title":"Nat. Prod. Bioprospect."},{"key":"10.1016\/j.ctarc.2026.101301_bib0014","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10555-022-10028-4","article-title":"Inflammatory bowel disease and carcinogenesis","volume":"41","author":"Nagao-Kitamoto","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ctarc.2026.101301_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.dld.2022.08.012","article-title":"Critical signaling pathways governing colitis-associated colorectal cancer: signaling, therapeutic implications, and challenges","volume":"55","author":"Xin","year":"2023","journal-title":"Dig. Liver. Dis."},{"key":"10.1016\/j.ctarc.2026.101301_bib0016","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3390\/cancers3033104","article-title":"Toll-like receptor 4 signaling integrates intestinal inflammation with tumorigenesis: lessons from the murine model of colitis-associated cancer","volume":"3","author":"Hernandez","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101301_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105663","article-title":"Inflammation: Biochemistry, cellular targets, anti-inflammatory agents and challenges with special emphasis on cyclooxygenase-2","volume":"121","author":"Kaur","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ctarc.2026.101301_bib0018","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1177\/15353702231151959","article-title":"TGF-\u03b2 receptor I inhibitor may restrict the induction of EMT in inflamed intestinal epithelial cells","volume":"248","author":"Ghorbaninejad","year":"2023","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ctarc.2026.101301_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113583","article-title":"Research progress on anti-inflammatory drugs for preventing colitis-associated colorectal cancer","volume":"144","author":"Wang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2022.105382","article-title":"Inhibition of epithelial SHH signaling exerts a dual protective effect against inflammation and epithelial-mesenchymal transition in inflammatory bowel disease","volume":"82","author":"Ghorbaninejad","year":"2022","journal-title":"Toxicol. In. Vitro"},{"key":"10.1016\/j.ctarc.2026.101301_bib0021","first-page":"11","article-title":"Chemically induced colitis-associated cancer models in rodents for pharmacological modulation: a systematic review","author":"Modesto","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2026.101301_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00281-012-0352-6","article-title":"Inflammation and colorectal cancer: colitis-associated neoplasia","volume":"35","author":"Grivennikov","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0023","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1158\/1940-6207.CAPR-09-0272","article-title":"Prevention of colitis-associated carcinogenesis with infliximab","volume":"3","author":"Kim","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0024","first-page":"560","article-title":"Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis","volume":"118","author":"Popivanova","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ctarc.2026.101301_bib0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.diff.2019.01.002","article-title":"Wnt signaling in intestinal inflammation","volume":"108","author":"Moparthi","year":"2019","journal-title":"Differentiation"},{"key":"10.1016\/j.ctarc.2026.101301_bib0026","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ctarc.2026.101301_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116580","article-title":"Erlotinib suppresses tumorigenesis in a mouse model of colitis-associated cancer","volume":"175","author":"Liu","year":"2024","journal-title":"Biomed. PharmacOther."},{"key":"10.1016\/j.ctarc.2026.101301_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117018","article-title":"Low-dose dimethylfumarate attenuates colitis-associated cancer in mice through M2 macrophage polarization and blocking oxidative stress","volume":"489","author":"Abdelaziz","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0029","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ctarc.2026.101301_bib0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4155\/fmc-2019-0307","article-title":"An overview of drug discovery and development","volume":"12","author":"Berdigaliyev","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ctarc.2026.101301_bib0031","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/17460441.2021.1972255","article-title":"How necessary are animal models for modern drug discovery?","volume":"16","author":"Singh","year":"2021","journal-title":"Expert. Opin. Drug Discov."},{"key":"10.1016\/j.ctarc.2026.101301_bib0032","article-title":"Animal models of colitis-associated carcinogenesis","volume":"2011","author":"Kanneganti","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0033","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41467-025-56690-4","article-title":"Drug repurposing for Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"16","author":"Cummings","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2026.101301_bib0034","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","article-title":"Discovery and resupply of pharmacologically active plant-derived natural products: a review","volume":"33","author":"Atanasov","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ctarc.2026.101301_bib0035","series-title":"Combination Therapy Against Multidrug Resistance","first-page":"1","article-title":"Chapter 1 - Combination therapy: current status and future perspectives","author":"Malik","year":"2020"},{"key":"10.1016\/j.ctarc.2026.101301_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1301093","article-title":"Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review","volume":"14","author":"Xie","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0037","article-title":"Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment","volume":"34","author":"Liu","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ctarc.2026.101301_bib0038","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1940-6207.CAPR-10-0033","article-title":"Novel application of proton pump inhibitor for the prevention of colitis-induced colorectal carcinogenesis beyond acid suppression","volume":"3","author":"Kim","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0039","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3390\/cimb45040189","article-title":"Infliximab inhibits colitis associated cancer in model mice by downregulating genes associated with mast cells and decreasing their accumulation","volume":"45","author":"Wang","year":"2023","journal-title":"Curr. Issues. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3164\/jcbn.20-189","article-title":"Chemoprevention by aspirin against inflammation-related colorectal cancer in mice","volume":"69","author":"Ohnishi","year":"2021","journal-title":"J. Clin. Biochem. Nutr."},{"key":"10.1016\/j.ctarc.2026.101301_bib0041","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/carcin\/bgw042","article-title":"The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice","volume":"37","author":"Guo","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctarc.2026.101301_bib0042","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/MIB.0000000000000303","article-title":"Effect of genetic deletion or pharmacological antagonism of tumor necrosis factor alpha on colitis-associated carcinogenesis in mice","volume":"21","author":"Craven","year":"2015","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ctarc.2026.101301_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114760","article-title":"Tigecycline reduces tumorigenesis in colorectal cancer via inhibition of cell proliferation and modulation of immune response","volume":"163","author":"Ruiz-Malag\u00f3n","year":"2023","journal-title":"Biomed. PharmacOther."},{"key":"10.1016\/j.ctarc.2026.101301_bib0044","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbi.2019.02.020","article-title":"Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota","volume":"80","author":"Sougiannis","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ctarc.2026.101301_bib0045","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/cas.12725","article-title":"Ghrelin administration suppresses inflammation-associated colorectal carcinogenesis in mice","volume":"106","author":"Kawaguchi","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ctarc.2026.101301_bib0046","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/jgh.12435","article-title":"Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer","volume":"29","author":"Koh","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113683","article-title":"Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4\/MyD88\/NF\u03baB\/MAPK pathway and macrophage M2 polarization","volume":"144","author":"Lai","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0048","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/mc.22274","article-title":"Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis","volume":"55","author":"Trivedi","year":"2016","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ctarc.2026.101301_bib0049","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ymthe.2022.10.014","article-title":"Therapeutic role of ursodeoxycholic acid in colitis-associated cancer via gut microbiota modulation","volume":"31","author":"He","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2026.101301_bib0050","first-page":"1","article-title":"Ursodeoxycholic acid alleviates dSS\/AOM-induced colorectal cancer in mice by inhibiting PI3K\/Akt\/mTOR signaling pathway","volume":"Volume 20","author":"Huang","year":"2026","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ctarc.2026.101301_bib0051","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99412-8","article-title":"Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1\/CCR2 pathway","volume":"11","author":"Hachiya","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101301_bib0052","doi-asserted-by":"crossref","first-page":"G968","DOI":"10.1152\/ajpgi.00346.2013","article-title":"Nicotine suppresses acute colitis and colonic tumorigenesis associated with chronic colitis in mice","volume":"307","author":"Hayashi","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver. Physiol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0053","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-74215-9","article-title":"Pravastatin prevents colitis-associated carcinogenesis by reducing CX3CR1(high) M2-like fibrocyte counts in the inflamed colon","volume":"14","author":"Hachiya","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101301_bib0054","first-page":"27","article-title":"Modern approaches in the discovery and development of plant-based natural products and their analogues as potential therapeutic agents","author":"Najmi","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.ctarc.2026.101301_bib0055","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/mnfr.201000225","article-title":"Chemopreventive effect of dietary curcumin on inflammation-induced colorectal carcinogenesis in mice","volume":"55","author":"Villegas","year":"2011","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0056","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1097\/MIB.0000000000000522","article-title":"The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention","volume":"21","author":"McFadden","year":"2015","journal-title":"Inflamm. Bowel. Dis."},{"key":"10.1016\/j.ctarc.2026.101301_bib0057","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/mc.22179","article-title":"Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice","volume":"54","author":"Li","year":"2015","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.ctarc.2026.101301_bib0058","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/labinvest.2017.71","article-title":"Berberine inhibits colitis-associated tumorigenesis via suppressing inflammatory responses and the consequent EGFR signaling-involved tumor cell growth","volume":"97","author":"Li","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ctarc.2026.101301_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154217","article-title":"Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora","volume":"102","author":"Yan","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ctarc.2026.101301_bib0060","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/nu14040726","article-title":"Pre-administration of berberine exerts chemopreventive effects in AOM\/DSS-induced colitis-associated carcinogenesis mice via modulating inflammation and intestinal microbiota","volume":"14","author":"Deng","year":"2022","journal-title":"Nutrients."},{"key":"10.1016\/j.ctarc.2026.101301_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175724","article-title":"Berberine induces SOCS1 pathway to reprogram the M1 polarization of macrophages via miR-155-5p in colitis-associated colorectal cancer","volume":"949","author":"Ling","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156665","article-title":"Formononetin suppresses colitis-associated colon cancer by targeting lipid synthesis and mTORC2\/Akt signaling","volume":"142","author":"Liu","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ctarc.2026.101301_bib0063","article-title":"Sulforaphane attenuates colitis-associated colorectal carcinogenesis: dual modulation of Wnt\/\u03b2-catenin signaling and gut microbial homeostasis in AOM\/DSS models","author":"Ma","year":"2025","journal-title":"Food Biosci."},{"key":"10.1016\/j.ctarc.2026.101301_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102431","article-title":"Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome","volume":"58","author":"Fan","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-11820-2","article-title":"Theabrownin combined with zearalenone suppresses colitis-associated colorectal cancer by inhibiting PI3K\/AKT pathway and enhancing microbial propionate production","volume":"15","author":"Leung","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101301_bib0066","article-title":"The role of tumor-associated macrophages in lung cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0067","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1535-7163.MCT-13-0378","article-title":"Embelin reduces colitis-associated tumorigenesis through limiting IL-6\/STAT3 signaling","volume":"13","author":"Dai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2026.101301_bib0068","doi-asserted-by":"crossref","first-page":"19548","DOI":"10.18632\/oncotarget.6969","article-title":"Macrophage targeting contributes to the inhibitory effects of embelin on colitis-associated cancer","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.ctarc.2026.101301_bib0069","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1541-7786.MCR-16-0101","article-title":"Combined parthenolide and balsalazide have enhanced antitumor efficacy through blockade of NF-\u03baB activation","volume":"15","author":"Kim","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0070","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1039\/C8FO01756E","article-title":"Synergy between dihydromyricetin intervention and irinotecan chemotherapy delays the progression of colon cancer in mouse models","volume":"10","author":"Zhu","year":"2019","journal-title":"Food Funct."},{"key":"10.1016\/j.ctarc.2026.101301_bib0071","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/1940-6207.CAPR-14-0128","article-title":"Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice","volume":"8","author":"Li","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0072","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.7150\/jca.13123","article-title":"Anti-inflammatory and antitumor activity of a triple therapy for a colitis-related colorectal cancer","volume":"7","author":"Figueroa-Gonz\u00e1lez","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101301_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175656","article-title":"Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells","volume":"946","author":"Liu","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0074","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s12011-022-03241-3","article-title":"Role of combination treatment of aspirin and zinc in DMH-DSS-induced colon inflammation, oxidative stress and tumour progression in male BALB\/c mice","volume":"201","author":"Babu","year":"2023","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bcp.2017.02.021","article-title":"Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq","volume":"135","author":"Guo","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0076","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1395954","article-title":"Feng-Liao-Chang-Wei-Kang combined with 5-fluorouracil synergistically suppresses colitis-associated colorectal cancer via the IL-6\/STAT3 signalling pathway","volume":"2020","author":"Zhong","year":"2020","journal-title":"Evid. Based. Complement. Alternat. Med."},{"key":"10.1016\/j.ctarc.2026.101301_bib0077","doi-asserted-by":"crossref","DOI":"10.1177\/10732748261430581","article-title":"Research progress on tumor-associated macrophages and PD-1\/PD-L1 inhibitors in advanced colorectal cancer","volume":"33","author":"Ning","year":"2026","journal-title":"Cancer Control"},{"key":"10.1016\/j.ctarc.2026.101301_bib0078","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.3390\/cancers14246131","article-title":"Cancer Immunotherapy: the checkpoint between chronic colitis and colorectal cancer","volume":"14","author":"Ephraim","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101301_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177704","article-title":"Combination therapy with cetirizine and anti-PD-1 antibody suppresses colitis-induced colon tumor formation in mice","volume":"999","author":"Maruyama","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101301_bib0080","first-page":"1","article-title":"Thimerosal inhibits tumor malignant progression through direct action and enhancing the efficacy of PD-1-based immunotherapy","volume":"34","author":"Wang","year":"2026","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116883","article-title":"Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing PD-L1 expression and optimizing the tumor microenvironment","volume":"176","author":"Jia","year":"2024","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.ctarc.2026.101301_bib0082","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.biomaterials.2016.06.018","article-title":"Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer","volume":"101","author":"Zhang","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.ctarc.2026.101301_bib0083","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.7150\/thno.38081","article-title":"Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer","volume":"9","author":"Han","year":"2019","journal-title":"Theranostics."},{"key":"10.1016\/j.ctarc.2026.101301_bib0084","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/01635581.2020.1771384","article-title":"Curcumin administered as micellar solution suppresses intestinal inflammation and colorectal carcinogenesis","volume":"73","author":"Seiwert","year":"2021","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.ctarc.2026.101301_bib0085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ecco-jcc\/jjz113","article-title":"Oral targeted delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated cancer","volume":"14","author":"Yang","year":"2020","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ctarc.2026.101301_bib0086","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1039\/D2BM00540A","article-title":"Orally administrable polyphenol-based nanoparticles achieve anti-inflammation and antitumor treatment of colon diseases","volume":"10","author":"Le","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ctarc.2026.101301_bib0087","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700428","article-title":"Newly designed silica-containing redox nanoparticles for oral delivery of novel TOP2 catalytic inhibitor for treating colon cancer","volume":"6","author":"Vong","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ctarc.2026.101301_bib0088","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/IJN.S270939","article-title":"Delivery of rapamycin by liposomes synergistically enhances the chemotherapy effect of 5-fluorouracil on colorectal cancer","volume":"Volume 16","author":"Chen","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ctarc.2026.101301_bib0089","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.2147\/IJN.S373777","article-title":"Rapamycin liposomes combined with 5-fluorouracil inhibits angiogenesis and tumor growth of APC ((Min\/+)) mice and AOM\/DSS-induced colorectal cancer mice","volume":"Volume 17","author":"Liu","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ctarc.2026.101301_bib0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/DDDT.S292417","article-title":"Self-nanoemulsifying drug delivery system of genkwanin: a novel approach for anti-colitis-associated colorectal cancer","volume":"Volume 15","author":"Yin","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ctarc.2026.101301_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118644","article-title":"Colon-specific microspheres loaded with puerarin reduce tumorigenesis and metastasis in colitis-associated colorectal cancer","volume":"570","author":"Deng","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ctarc.2026.101301_bib0092","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13020-018-0177-x","article-title":"Techniques for extraction and isolation of natural products: a comprehensive review","volume":"13","author":"Zhang","year":"2018","journal-title":"Chin. Med."},{"key":"10.1016\/j.ctarc.2026.101301_bib0093","doi-asserted-by":"crossref","first-page":"81112","DOI":"10.1007\/s11356-022-23337-6","article-title":"Extraction and characterization of phenolic compounds and their potential antioxidant activities","volume":"29","author":"Shi","year":"2022","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"10.1016\/j.ctarc.2026.101301_bib0094","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11051-023-05690-w","article-title":"Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review","volume":"25","author":"Abbasi","year":"2023","journal-title":"J. NanoPart Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0095","doi-asserted-by":"crossref","unstructured":"A. Thakur, A. Kumar, Strategies for enhancing biocompatibility of nanoparticles, nanoparticle toxicity and compatibility 2024, pp. 182-224.","DOI":"10.21741\/9781644902998-7"},{"key":"10.1016\/j.ctarc.2026.101301_bib0096","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","article-title":"Nanomedicine scale-up technologies: feasibilities and challenges","volume":"15","author":"Paliwal","year":"2014","journal-title":"AAPS. PharmSciTech."},{"key":"10.1016\/j.ctarc.2026.101301_bib0097","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/bs.pbr.2014.12.008","article-title":"Bench to bedside: challenges of clinical translation","volume":"218","author":"Steeves","year":"2015","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ctarc.2026.101301_bib0098","doi-asserted-by":"crossref","unstructured":"S. Sinha, D. Vohora, Drug discovery and development: an overview, pharmaceutical medicine and translational clinical research 2018, pp. 19-32.","DOI":"10.1016\/B978-0-12-802103-3.00002-X"},{"key":"10.1016\/j.ctarc.2026.101301_bib0099","first-page":"53","article-title":"Research reliability and validity: why do they matter?","volume":"98","author":"Olmsted","year":"2024","journal-title":"J. Dent. Hyg."},{"key":"10.1016\/j.ctarc.2026.101301_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124518","article-title":"Bile salt integrated cerasomes: a potential nanocarrier for enhancement of the oral bioavailability of idarubicin hydrochloride","volume":"662","author":"Emzhik","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ctarc.2026.101301_bib0101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s43094-023-00569-y","article-title":"Pharmacokinetics of nanoparticles: current knowledge, future directions and its implications in drug delivery","volume":"9","author":"Haripriyaa","year":"2023","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.ctarc.2026.101301_bib0102","article-title":"From bench to bedside: a review of clinical trials in drug discovery and development","volume":"7","author":"Wang","year":"2024","journal-title":"BIOI"},{"key":"10.1016\/j.ctarc.2026.101301_bib0103","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/ecco-jcc\/jjad020","article-title":"Declining enrolment and other challenges in IBD clinical trials: causes and potential solutions","volume":"17","author":"Uzzan","year":"2023","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ctarc.2026.101301_bib0104","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO Guidelines on inflammatory bowel disease and malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J. Crohns. Colitis."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:47:03Z","timestamp":1790912823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":104,"alternative-id":["S2468294226002121"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101301","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological approaches for colitis associated colorectal cancer: a survey in preclinical studies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101301"}}